Clazosentan disappointment for Actelion will prompt Conscious decision within month
This article was originally published in Scrip
Actelion, one of Europe's leading biopharmaceutical companies, may have to abandon one of its Phase III programmes after unveiling disappointing results from a study of clazosentan for aneurismal subarachnoid haemorrhage (aSAH). While analysts had a pretty dim view of the molecule's chances of success and so had assigned very little value to the programmes, the company's share price still dropped CHF4.18 to CHF39.28 (9.6%), wiping CHF540 million ($550 million) off the company's value.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.